Shiyi Zhou

Dr. Shiyi Zhou


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2024 in Kidney Diseases
Verified
Journal Article
Open access
PDF file
ZHZhongyu Han
Zhongyu Han
YLYuanke Luo
Yuanke Luo
HCHaoran Chen
Haoran Chen
GZGuochen Zhang
Guochen Zhang
LYLuling You
Luling You
SZShiyi Zhou
Shiyi Zhou
Background: Ferroptosis, a newly recognized form of programmed cell death, is distinguished by its reliance on reactive oxygen species and iron-mediated lipid peroxidation, setting it apart from established types like apoptosis, cell necrosis, and autophagy. Recent studies suggest its role in exacerbating or mitigating diseases by influencing metabolic and signaling pathways in conditions such as tumors and ischemic organ damage. Evidence also links ferroptosis to various kidney diseases, prompting a review of its research status and potential breakthroughs in understanding and treating these conditions. Summary: In acute kidney disease (AKI), ferroptosis has been confirmed in animal kidneys after being induced by various factors such as renal ischemia-reperfusion and cisplatin, and glutathione peroxidase 4 (GPX4) is linked with AKI. Ferroptosis is associated with renal fibrosis in chronic kidney disease (CKD), TGF-β1 being crucial in this regard. In diabetic nephropathy (DN), high SLC7A11 and low nuclear receptor coactivator 4 (NCOA4) expressions are linked to disease progression. For polycystic kidney disease (PKD), ferroptosis promotes the disease by regulating ferroptosis in kidney tissue. Renal cell carcinoma (RCC) and lupus nephritis (LN) also have links to ferroptosis, with mtDNA and iron accumulation causing RCC and oxidative stress causing LN. Key Messages: Ferroptosis is a newly identified form of programmed cell death that is associated with various diseases. It targets metabolic and signaling pathways and has been linked to kidney diseases such as AKI, CKD, PKD, DN, LN, and clear cell RCC. Understanding its role in these diseases could lead to breakthroughs in their pathogenesis, etiology, and treatment.

1 October 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
YLYanping Li
Yanping Li
XXXiaoqian Xiao
Xiaoqian Xiao
HWHuili Wang
Huili Wang
QZQi Zhou
Qi Zhou
ZJZhao Jin
Zhao Jin
JYJiahui Yang
Jiahui Yang

25 July 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
YWYi Wang
Yi Wang
YZYuxi Zhang
Yuxi Zhang
HSHaoyi Sun
Haoyi Sun
JCJilan Chen
Jilan Chen
HYHui Yang
Hui Yang
JYJiahui Yang
Jiahui Yang

6 May 2023 in Phytomedicine
Verified
Journal Article
Closed access
YLYile Liao
Yile Liao
SLShengrong Li
Shengrong Li
JAJun An
Jun An
XYXiankuo Yu
Xiankuo Yu
XTXue Tan
Xue Tan
DWDong Wang
Dong Wang

27 August 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GZGuochen Zhang
Guochen Zhang
LXLei Xiang
Lei Xiang
QLQingzhou Li
Qingzhou Li
MWMingming Wei
Mingming Wei
XYXiankuo Yu
Xiankuo Yu
SZShiyi Zhou
Shiyi Zhou
Background: Prostate cancer (PCa) is the primary contributor to male cancer-related mortality and currently lacks effective treatment options. The Modified Guizhi Fuling Decoction (MGFD) is used in clinical practice to treat multiple tumors. This research focused on the mechanisms of action (MOA) in MGFD that inhibit PCa. Methods: The impact of MGFD on PCa cells (PC3 and DU145) was examined via Cell Counting Kit-8, wound healing assays, and transwell assays. To determine the MOA, high-throughput sequencing based high-throughput screening (HTS2) was utilized along with network pharmacology. Results: The findings indicated that MGFD suppressed the proliferation, migration, and invasion of PCa cells. We then utilized the HTS2 assay to generate 270 gene expression profiles from PCa cells perturbed by MGFD. Large-scale transcriptional analysis highlighted three pathways closely associated with PCa: the TNF signaling pathway, cellular senescence, and FoxO signaling pathway. Through the combination of network pharmacology and bioinformatics, we discovered four primary targets through which MGFD acts on PCa: AKT serine/threonine kinase 1 (AKT1), Caspase-8 (CASP8), Cyclin-Dependent Kinase 1 (CDK1), and Cyclin D1 (CCND1). Finally, molecular docking demonstrated that the potential bioactive compounds baicalein, quercetin, and 5-[[5-(4-methoxyphenyl)-2-furyl] methylene] barbituric acid strongly bind to CDK1, AKT1, and CASP8, respectively. Conclusions: This research shows that MGFD displays encouraging anticancer effects via various mechanisms. Its multi-target activity profile underscores its promise as a potential therapeutic option for PCa treatment and encourages additional in vivo validation studies.